Results from a landmark European HEYMANS study show that Evolocumab treatment has demonstrated the capacity to influence substantial reductions in LDL-C levels for an extended duration. To delve deeper into the details, listen to this podcast now.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
